Last updated: February 24, 2026
What is the drug identified by NDC 70000-0719?
NDC 70000-0719 refers to a specific pharmaceutical product, which in this case is Fenofibrate 160 mg capsules. Fenofibrate is prescribed primarily for reducing triglycerides and LDL cholesterol levels in patients with hyperlipidemia.
What is the current market landscape for Fenofibrate?
Market Size and Sales Data
- The global hyperlipidemia drugs market was valued at approximately $14 billion in 2022 (Grand View Research).
- Fenofibrate accounted for roughly 20% of the statin and fibrate segment, translating to an annual U.S. sales volume of an estimated $2.8 billion.
- The drug has seen steady demand over recent years due to its role in cardiovascular risk management.
Major Market Players
- AbbVie (original manufacturer of Tricor and Triglide)
- Teva Pharmaceuticals
- Mylan (now part of Viatris)
- Sun Pharmaceutical
- Hikma Pharmaceuticals
Patent Status
- Fenofibrate patents have expired or are close to expiration in key markets (U.S., Europe).
- Market share shifts toward generic formulations have increased price sensitivity.
How do pricing dynamics evolve for Fenofibrate?
Current Pricing Metrics
- Brand-name Tricor (AbbVie's product): approximately $400–$450 for a 30-day supply (30 capsules of 160 mg).
- Generic Fenofibrate: approximately $10–$20 for a 30-day supply.
Price Trends
- Generic formulations have driven prices down by over 90% since patent expiration.
- Wholesale acquisition costs (WAC) for generics in 2023 ranged from $0.33 to $0.67 per capsule.
- Retail pharmacy cash prices are typically $5–$15 for a 30-day supply.
What are the key factors influencing future price projections?
Patent and Regulatory Outlook
- The primary patent for the brand product expired in the U.S. in 2015; related patents for formulation methods expired in 2019.
- Pending or potential new formulations (e.g., combination pills, controlled-release variants) could impact pricing strategies.
Market Penetration and Competition
- Market penetration by generic suppliers continues to increase.
- Competition among multiple generics maintains downward pressure.
- Emerging markets are expanding access, which may boost overall volume but reduce premium pricing.
Healthcare Policy & Reimbursement Trends
- Shift toward formulary restrictions favors low-cost generics.
- Insurance reimbursements favor cost-effective options, limiting price increases for branded versions.
Forecasting Price Trends
| Year |
Generic Capsule Price (approx.) |
Brand Price (approx.) |
Market Share of Generics |
Key Drivers |
| 2023 |
$0.33–$0.67 |
$400–$450 |
80–90% |
Patent expiry, increased competition |
| 2025 |
$0.40–$0.75 |
$370–$410 |
85–90% |
Further generic penetration, market saturation |
Price Projections for 2025–2030
- Generics will maintain prices between $0.35 and $0.80 per capsule.
- Brand-name prices are likely to stabilize around $350–$400, with limited upward movement due to patent expiration and competitive pressures.
- Regional differences may cause deviations, with emerging markets seeing lower prices and mature markets maintaining slight premiums for branded products.
What are the implications for stakeholders?
For Manufacturers
- Focus on formulary placement and price competition.
- Explore innovative delivery methods or combination therapies to sustain premium pricing.
- Monitor patent litigation and formulation patents to anticipate market shifts.
For Investors
- Anticipate stable high-volume sales driven by generics.
- Recognize limited pricing upside in mature markets.
- Explore opportunities in emerging markets with lower price points but higher volume potential.
For Healthcare Providers
- Favor low-cost generic options to control costs.
- Consider patient adherence with fixed-dose combination therapies.
Summary of Key Price Drivers
- Patent status
- Competition level
- Market penetration
- Regulatory environment
- Regional healthcare policies
Key Takeaways
- NDC 70000-0719 (Fenofibrate 160 mg) exists predominantly as a generic product with low per-unit costs.
- Market has shifted from branded to generics, with prices falling sharply post-patent expiration.
- Future price stabilization is expected, with minor fluctuations influenced by market saturation and regulatory factors.
- Volume growth may offset limited price increases, especially in emerging markets.
- Stakeholders should focus on market access, formulation innovation, and regional dynamics for strategic positioning.
FAQs
1. Will the price of Fenofibrate increase again?
Prices are unlikely to increase significantly due to patent expirations and intense generic competition. Small increases may occur if new formulations or combination products are introduced.
2. Are there any new formulations that could affect pricing?
Yes. Extended-release versions or combination therapies could command higher prices but are subject to clinical approval and patent protections.
3. How does regional pricing vary?
Emerging markets generally have lower prices due to lower healthcare spending and regulatory differences; mature markets see higher per-unit costs and more brand presence.
4. What is the outlook for branded Fenofibrate?
Branded products will likely retain niche markets or premium segments, but overall contribution to sales will diminish as generics dominate.
5. How might policy changes influence future prices?
Policies favoring generic utilization and cost containment could keep prices low; restrictive reimbursement policies could limit price increases even for branded versions.
References
[1] Grand View Research. (2022). Hyperlipidemia Drugs Market Size, Share & Trends.
[2] GoodRx. (2023). Fenofibrate Cost & Price.
[3] U.S. Food and Drug Administration. (2015). Patent status of Fenofibrate.
